Myriad Receives Reimbursement Decision For MyChoice Diagnostic System
TOKYO (dpa-AFX) - Myriad Genetics, Inc. (MYGN) said it received first reimbursement decision for the myChoice Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula. myChoice was approved by Japan s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication.
Myriad has been collaborating with Takeda Pharma in Japan since 2017 on the development of companion diagnostics. The company has partnered with SRL Inc. to commercialize the myChoice Diagnostic System in Japan.
Copyright RTT News/dpa-AFX
© 2021 AFX News
News - Immuno-oncology, Switzerland, Focus On
thepharmaletter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepharmaletter.com Daily Mail and Mail on Sunday newspapers.
Japan s chemical industry inches toward gender diversity
acs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acs.org Daily Mail and Mail on Sunday newspapers.